| ID | 1107 |
| Name of the vaccine | BCG |
| Microbe | Bacteria |
| Disease name | Leprosy |
| Name of bacteria | Mycobacterium leprae |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | Under 1 year |
| Description of the vaccine | BCG has significant protective efficacy against severe TB in children and against leprosy in adults. |
| Name of the manufacturer | Organon Teknika Corporation LLC |
| Name of the manufacturing country | Durham |
| Year of manufacture | 1921 |
| Clinical Phase status | Approved |
| Bacterial strain | Acid fast gram-positive bacteria. |
| Efficacy | Efficacy against leprosy ranged from 26 to 41% in experimental studies to 61% in observational studies. |
| Vaccine formulation | Lyophilized (freeze-dried) powder |
| Dosage | Adults: 1 mL of Sterile Water for Injection added to one vial.
Infants (less than 1 month): 2 mL of Sterile Water for Injection. |
| Mechanism of action | Th-1 cell mediated and activate antigen-specific CD4+ T-cells. |
| Route of administration | Percutaneous |
| Indications | Prevention against tuberculosis and leprosy. |
| Export | Distributed by - Organon USA Inc. Roseland |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For pulmonary tuberculosis. |
| Side effects of vaccine | Cervical lymphadenopathy, induration, pustule formation, ulceration, regional suppurative lymphadenitis with draining sinuses, caseous lesions and disseminated BCG infection. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 29535713 |
| Clinical trial number | NA |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|